Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program
- 27 December 2010
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (3) , 443-453
Abstract
Background: PR‐104 is rapidly hydrolyzed to PR‐104A in vivo, which is activated by reduction to the corresponding 5‐hydroxylamine (PR‐104H) and amine (PR‐104M) to produce DNA interstrand cross‐links. PR‐104 activation can occur via hypoxia‐dependent reductases and also independently of hypoxia by aldo‐keto reductase (AKR) 1C3.Procedures: PR‐104A was tested against the PPTP in vitro panel (10 nM to 100 µM), and PR‐104 in vivo using a weekly × 6 schedule at its maximum tolerated dose (MTD) of 550 mg/kg. Subsequently PR‐104 was tested at 270 and 110 mg/kg. Pharmacokinetics for PR‐104 and its metabolites were determined, as were levels of AKR1C3 RNA and protein in xenografts.Results: In vitro, the leukemia models were most sensitive to PR‐104A. In vivo, PR‐104 induced objective responses at its MTD in 21/34 solid tumor models and maintained complete responses against 7/7 acute lymphoblastic leukemia (ALL) models. At 270 mg/kg and lower dose levels, PR‐104 did not induce solid tumor regressions, suggesting a steep dose–response relationship. Pharmacokinetic analysis suggests higher systemic exposures to PR‐104A and its metabolites in mice compared to those achievable in patients. Levels of AKR1C3 protein did not correlate with tumor responsiveness.Conclusions: As monotherapy, PR‐104 demonstrated a high level of activity against both solid tumor and ALL models at its MTD, but the activity was almost completely lost at half the MTD dose for solid tumors. Pharmacokinetic data at the PR‐104 MTD from human trials suggest that PR‐104 metabolites may not reach the plasma exposures in children that were associated with high‐level preclinical activity. Pediatr Blood Cancer 2011; 57: 443–453.Keywords
Funding Information
- National Cancer Institute (NO1-CM-42216, CA21765, CA108786)
- Health Research Council of New Zealand (HRC08/103)
This publication has 40 references indexed in Scilit:
- National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testingPediatric Blood & Cancer, 2010
- Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and HumansDrug Metabolism and Disposition, 2010
- The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3Cancer Research, 2010
- Noninvasive Molecular Imaging of Hypoxia in Human Xenografts: Comparing Hypoxia-Induced Gene Expression with Endogenous and Exogenous Hypoxia MarkersCancer Research, 2008
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPediatric Blood & Cancer, 2007
- Hypoxia-driven selection of the metastatic phenotypeCancer and Metastasis Reviews, 2007
- A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinationsMolecular Cancer Therapeutics, 2007
- Improved Response in High-Risk Neuroblastoma With Protracted Topotecan Administration Using a Pharmacokinetically Guided Dosing ApproachJournal of Clinical Oncology, 2005
- Integrating pharmacology and in vivo cancer models in preclinical and clinical drug developmentEuropean Journal of Cancer, 2004
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumoursNature, 1996